Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System
Phase II Study of Antineoplastons A10 and AS2-1 in Children With Rhabdoid Tumor of the Central Nervous System
Sponsor: Burzynski Research Institute
Terminated
Slow accrual
Other terminated trials from Burzynski Research Institute
A PHASE2 clinical study on Rhabdoid Neoplasm of CNS, this trial is terminated or withdrawn. The trial is conducted by Burzynski Research Institute and has accumulated 9 data snapshots since 1996. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Feb 2017 — May 2017 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE2
First recorded
Feb 1996
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Burzynski Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .